Xlear today announced a new partnership with Dr. Ferrer BioPharma (DFBP) that will make Xlear Nasal Spray the first nasal hygiene tool to implement the GentleMist Diffuser, the next generation of nasal spray technology which, like the has been shown in research, improves compound dispersion, coverage and wearability.
Studies on nasal cleansing have already identified that washing the nose and nasal cavity is an important practice for improving health and well-being. Several clinical and laboratory studies have shown that nasal hygiene is an important complement in the fight against rhinositis and various bacterial and viral infections.
New research published by the European Society of Medicine has identified that the GentleMist Diffuser achieves more even and complete dispersion of nasal sprays in the nose and nasal cavity. The study also found that the new diffuser was smoother and significantly improved the user experience compared to conventional nasal spray technologies. Read the full study by clicking here: Patient experience evaluation for a computer-guided intranasal spray protocol to increase therapeutic penetration: implications for effective treatments for COVID-19, rhinitis and sinusitis | Archives of Medical Research (esmed.org)
Subscribe to THE POVO+
Access all exclusive content, columnists, unlimited access and discounts at stores, pharmacies and more.
Nasal sprays have traditionally adopted a conventional pattern where the spray is applied directly to the airways in the direction in which it is sprayed. The new diffuser is very smooth and the spray is applied in a vortex/swirl pattern. This is extremely important and beneficial to Xlear and its customers as it allows the Xlear compound (saline solution, xylitol and grapefruit seed extract) to be applied much more effectively and completely into the nose and nasal cavity.
“Millions of people have used and benefited from our nasal spray for over 20 years, and we are very excited to make this new technology available so they have an even better experience. We realize that if you wash your nose morning and night is uncomfortable, irritating or even slightly hurtful, people will not adopt this practice often enough to have an effective effect.If we hurt ourselves every time we wash our hands or brush our teeth, we will not adopt neither do these hygiene practices often. hands, showering or brushing teeth, washing our nose provides an extra layer of protection to keep us clean and healthy and breathe easier throughout the day,” said said Nate Jones, CEO of Xlear.
Xlear does not seek to diagnose, treat, cure or prevent any disease.
Founded in 2000, Xlear, Inc. is recognized as the leading manufacturer of natural, proactive xylitol health care products. Xlear is committed to providing its customers with the highest quality products and strives to educate medical and dental professionals, as well as their patients, about how using xylitol in place of sugar can lead to a much healthier and happier life. . Xlear is backed by a team of physicians, hygienists, and scientists who champion the use and benefits of xylitol through ongoing medical research. Xlear, Inc. offers Xlear Nasal Spray, an award-winning, patented saline nasal solution containing xylitol; a full line of oral health products offered as part of the Spry Dental Defense System; and Lite&Sweet, a xylitol and erythritol sweetener used as a sugar substitute in cooking, baking and general consumption. Learn more at www.xlear.com.
About Dr. Ferrer BioPharma
Dr. Ferrer BioPharma is the leading innovator of intranasal medications to treat coughs, flu, colds and allergies. Dr. Ferrer BioPharma uses advanced nanoparticle technology to deliver high-quality, evidence-based, consumer-focused, doctor-invented products. Its mission is to provide the market with evidence-based therapies that combine new ideas with proven concepts to help people. From molecules to delivering effective therapies to treat the populations we serve, Dr. Ferrer BioPharma develops the best intranasal treatments to help people breathe easier. To learn more, visit www.drferrerbiopharma.com.
The original text of this announcement is the official authorized version. Translations are provided for convenience only and should refer to the text in the original language, which is the only version of the text with legal effect.
View the original version on businesswire.com: https://www.businesswire.com/news/home/20220516005271/en/
Jeff Gulko Xlear Inc. 617.304.7339 [email protected]
© 2022 BusinessWire, Inc. Disclaimer: This document is not produced by AFP and AFP cannot be held responsible for its content. If you have any questions regarding the content, please contact the persons/companies indicated in this press release.
Questions, criticisms and suggestions? Talk to us